NCT04484142 2026-03-17Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)Daiichi SankyoPhase 2 Completed137 enrolled 9 charts 1 FDA
NCT04886804 2026-03-13Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)Boehringer IngelheimPhase 1 Active not recruiting608 enrolled 2 FDA
NCT05099172 2026-03-12First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)BayerPhase 1/2 Active not recruiting370 enrolled 1 FDA
NCT05091567 2026-03-10IMforteHoffmann-La RochePhase 3 Active not recruiting660 enrolled 23 charts 1 FDA
NCT02716116 2026-02-25A Study of TAK-788 in Adults With Non-Small Cell Lung CancerTakedaPhase 1/2 Active not recruiting334 enrolled 1 FDA
NCT04538664 2026-02-25PAPILLONJanssen Research & Development, LLCPhase 3 Active not recruiting308 enrolled 12 charts 1 FDA
NCT03088540 2026-02-23Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)Regeneron PharmaceuticalsPhase 3 Completed712 enrolled 1 FDA